Skip to main content
Erschienen in: Investigational New Drugs 6/2014

01.12.2014 | PHASE I STUDIES

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

verfasst von: Rastislav Bahleda, Cristiana Sessa, Gianluca Del Conte, Luca Gianni, Giuseppe Capri, Andrea Varga, Corina Oprea, Byzance Daglish, Marie Hospitel, Jean-Charles Soria

Erschienen in: Investigational New Drugs | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Summary

Purpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy agents. Ombrabulin was combined with two standard taxane/platinum doublets in a phase I study to determine the recommended combination doses. Methods Ombrabulin (30-min infusion, day 1 every 3 weeks) was escalated from 15.5 to 35 mg/m2 with two chemotherapy doublets; OCD, 75 mg/m2 cisplatin (C), day 1 (cohort 1) or day 2 (cohort 2) with 60/75 mg/m2 docetaxel (D), day 2; and OCP, AUC5/6 carboplatin (C) and paclitaxel (P) 175 mg/m2 (cohort 3) or 200 mg/m2 (cohort 4), day 2. Safety, pharmacokinetics, and tumor response were evaluated. Results Sixty-nine patients were treated (32 OCD, 37 OCP). Four had DLTs in cycle 1, two in cohort 1 (grade 4 febrile neutropenia, grade 4 pulmonary embolism) and one each in cohorts 2 (grade 3 ALT elevation) and 4 (grade 3 peripheral ischemia). Ombrabulin escalation in cohorts 2, 3 and 4 was halted at the highest planned dose (35 mg/m2). Asthenia, nausea, paresthesia, alopecia, vomiting, and stomatitis were common, as was grade 3–4 neutropenia. Ombrabulin clearance was high with a short terminal half-life and a medium volume of distribution. Pharmacokinetic analysis showed no clinically relevant drug interactions between the taxane-platinum doublet and ombrabulin or its active metabolite RPR258063, however docetaxel and carboplatin pharmacokinetics were slightly altered. One complete and 15 partial responses (10 OCD, 5 OCP; median duration 5.5 and 4.4 months, respectively) were reported. Conclusions The addition of ombrabulin to standard doses of cisplatin/docetaxel or carboplatin/paclitaxel proved feasible with manageable overlapping toxicities but appears to have limited impact on the efficacy of these doublets. Recommended combination doses are 35 mg/m2 ombrabulin with 75 mg/m2 cisplatin/75 mg/m2 docetaxel or 200 mg/m2 paclitaxel/AUC6 carboplatin, every 3 weeks.
Literatur
1.
Zurück zum Zitat McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116:1859–1871CrossRefPubMed McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116:1859–1871CrossRefPubMed
2.
Zurück zum Zitat Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T et al (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387–1395CrossRefPubMed Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T et al (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387–1395CrossRefPubMed
3.
Zurück zum Zitat Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604–1614PubMedCentralCrossRefPubMed Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604–1614PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Clemenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E (2012) The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 31:273–284CrossRefPubMed Clemenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E (2012) The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 31:273–284CrossRefPubMed
5.
Zurück zum Zitat Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A et al (2013) Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res 19:4832–4842CrossRefPubMed Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A et al (2013) Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res 19:4832–4842CrossRefPubMed
6.
Zurück zum Zitat Soria J, Sessa C, Perotti A, Massard C, Armand J, Lassaud N et al. (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. Proceedings of the American Association for Cancer Research 99th Annual Meeting; Abstract LB-302. Soria J, Sessa C, Perotti A, Massard C, Armand J, Lassaud N et al. (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. Proceedings of the American Association for Cancer Research 99th Annual Meeting; Abstract LB-302.
7.
Zurück zum Zitat Eskens F, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A et al (2014) A phase I dose escalation and pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) combined with docetaxel in advanced solid tumors. Br J Cancer 110:2170–2177PubMedCentralCrossRefPubMed Eskens F, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A et al (2014) A phase I dose escalation and pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) combined with docetaxel in advanced solid tumors. Br J Cancer 110:2170–2177PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–172CrossRefPubMed Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–172CrossRefPubMed
9.
Zurück zum Zitat Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–196PubMed Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–196PubMed
10.
Zurück zum Zitat Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963–4970CrossRefPubMed Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963–4970CrossRefPubMed
11.
Zurück zum Zitat Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMed Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMed
12.
Zurück zum Zitat Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I et al (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965–2971CrossRefPubMed Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I et al (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965–2971CrossRefPubMed
13.
Zurück zum Zitat Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829–2836CrossRefPubMed Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829–2836CrossRefPubMed
14.
Zurück zum Zitat du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S et al (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370–375CrossRefPubMed du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S et al (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370–375CrossRefPubMed
15.
Zurück zum Zitat Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J et al (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:2036–2041CrossRefPubMed Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J et al (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:2036–2041CrossRefPubMed
16.
Zurück zum Zitat Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMed Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMed
17.
18.
Zurück zum Zitat Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K et al (2006) A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cancer Chemother Pharmacol 58:673–680CrossRefPubMed Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K et al (2006) A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cancer Chemother Pharmacol 58:673–680CrossRefPubMed
19.
Zurück zum Zitat Vergote I, Amant F, Oskay-Oezcelik G, Musib L, Michel AL, Darstein C et al (2009) Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study. Int J Gynecol Cancer 19:1505–1510CrossRefPubMed Vergote I, Amant F, Oskay-Oezcelik G, Musib L, Michel AL, Darstein C et al (2009) Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study. Int J Gynecol Cancer 19:1505–1510CrossRefPubMed
20.
Zurück zum Zitat Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K et al (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208–215CrossRefPubMed Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K et al (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208–215CrossRefPubMed
21.
Zurück zum Zitat Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C et al (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651–661PubMed Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C et al (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651–661PubMed
22.
Zurück zum Zitat Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M (2003) Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94:200–204CrossRefPubMed Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M (2003) Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94:200–204CrossRefPubMed
23.
Zurück zum Zitat Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692–1703PubMed Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692–1703PubMed
24.
Zurück zum Zitat Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M et al (2007) Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97:888–894PubMedCentralPubMed Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M et al (2007) Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97:888–894PubMedCentralPubMed
Metadaten
Titel
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
verfasst von
Rastislav Bahleda
Cristiana Sessa
Gianluca Del Conte
Luca Gianni
Giuseppe Capri
Andrea Varga
Corina Oprea
Byzance Daglish
Marie Hospitel
Jean-Charles Soria
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 6/2014
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-014-0119-0

Weitere Artikel der Ausgabe 6/2014

Investigational New Drugs 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.